• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 N-乙酰半胱氨酸和壳聚糖的结构化脂质载体(MLC)预防生物膜。

Microstructured Lipid Carriers (MLC) Based on N-Acetylcysteine and Chitosan Preventing Biofilm.

机构信息

Department of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.

出版信息

Int J Mol Sci. 2021 Jan 17;22(2):891. doi: 10.3390/ijms22020891.

DOI:10.3390/ijms22020891
PMID:33477393
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7830306/
Abstract

The aim of this work was the development of microstructured lipid carriers (MLC) based on chitosan (CH) and containing N-acetylcysteine (NAC), a mucolytic and antioxidant agent, to inhibit the formation of biofilm. MLC were prepared using the high shear homogenization technique. The MLC were characterized for morphology, particle size, Z potential, encapsulation efficiency and drug release. The antioxidant properties of NAC-loaded microstructured carriers were evaluated through an in vitro spectrophotometer assay. Finally, the activity of NAC-CH-MLC on biofilm production by was also evaluated. Results obtained from this study highlighted that the use of chitosan into the inner aqueous phase permitted to obtain microstructured particles with a narrow size range and with good encapsulation efficiency. NAC-loaded MLC showed higher antioxidant activity than the free molecule, demonstrating how encapsulation increases the antioxidant effect of the molecule. Furthermore, the reduction of biofilm growth resulted extremely high with MLC being 64.74% ± 6.2% and 83.74% ± 9.95%, respectively, at 0.5 mg/mL and 2 mg/mL. In conclusion, this work represents a favorable technological strategy against diseases in which bacterial biofilm is relevant, such as cystic fibrosis.

摘要

本工作的目的是开发基于壳聚糖(CH)的结构化脂质载体(MLC),并包含粘蛋白溶解剂和抗氧化剂 N-乙酰半胱氨酸(NAC),以抑制生物膜的形成。MLC 是使用高剪切匀浆技术制备的。对 MLC 的形态、粒径、Z 电位、包封效率和药物释放进行了表征。通过体外分光光度计测定法评估了负载 NAC 的结构化载体的抗氧化特性。最后,还评估了 NAC-CH-MLC 对生物膜生成的活性。本研究结果表明,在水相内部使用壳聚糖可以获得具有较窄粒径范围和良好包封效率的结构化颗粒。负载 NAC 的 MLC 表现出比游离分子更高的抗氧化活性,表明包封增加了分子的抗氧化作用。此外,当浓度分别为 0.5mg/mL 和 2mg/mL 时,MLC 对生物膜生长的抑制率极高,分别为 64.74%±6.2%和 83.74%±9.95%。总之,这项工作代表了一种针对与细菌生物膜相关的疾病(如囊性纤维化)的有利技术策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/0f328be6db6a/ijms-22-00891-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/a1cedf1a8ba8/ijms-22-00891-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/6475adb15e25/ijms-22-00891-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/be2477da7de0/ijms-22-00891-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/7a626c3a05fc/ijms-22-00891-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/1bdcaa315e68/ijms-22-00891-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/60534d8e1fc2/ijms-22-00891-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/f719e50db841/ijms-22-00891-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/8e71373abe7c/ijms-22-00891-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/b6bb0b1a4de1/ijms-22-00891-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/0f328be6db6a/ijms-22-00891-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/a1cedf1a8ba8/ijms-22-00891-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/6475adb15e25/ijms-22-00891-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/be2477da7de0/ijms-22-00891-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/7a626c3a05fc/ijms-22-00891-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/1bdcaa315e68/ijms-22-00891-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/60534d8e1fc2/ijms-22-00891-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/f719e50db841/ijms-22-00891-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/8e71373abe7c/ijms-22-00891-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/b6bb0b1a4de1/ijms-22-00891-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7beb/7830306/0f328be6db6a/ijms-22-00891-g010.jpg

相似文献

1
Microstructured Lipid Carriers (MLC) Based on N-Acetylcysteine and Chitosan Preventing Biofilm.基于 N-乙酰半胱氨酸和壳聚糖的结构化脂质载体(MLC)预防生物膜。
Int J Mol Sci. 2021 Jan 17;22(2):891. doi: 10.3390/ijms22020891.
2
Activity of -Acetylcysteine Alone and in Combination with Colistin against Pseudomonas aeruginosa Biofilms and Transcriptomic Response to -Acetylcysteine Exposure.α-乙酰半胱氨酸单独及与黏菌素联合对铜绿假单胞菌生物膜的活性以及对α-乙酰半胱氨酸暴露的转录组反应
Microbiol Spectr. 2022 Aug 31;10(4):e0100622. doi: 10.1128/spectrum.01006-22. Epub 2022 Jun 23.
3
In vitro inhibitory activity of N-acetylcysteine on tympanostomy tube biofilms from methicillin-resistant Staphylococcus aureus and quinolone-resistant Pseudomonas aeruginosa.N-乙酰半胱氨酸对耐甲氧西林金黄色葡萄球菌和耐喹诺酮铜绿假单胞菌鼓膜置管生物膜的体外抑制活性
Int J Pediatr Otorhinolaryngol. 2019 Nov;126:109622. doi: 10.1016/j.ijporl.2019.109622. Epub 2019 Aug 6.
4
Alginate lyase immobilized chitosan nanoparticles of ciprofloxacin for the improved antimicrobial activity against the biofilm associated mucoid P. aeruginosa infection in cystic fibrosis.壳聚糖固定化褐藻胶裂解酶纳米粒载环丙沙星提高对囊性纤维化患者铜绿假单胞菌生物膜相关黏液型感染的抗菌活性
Int J Pharm. 2019 May 30;563:30-42. doi: 10.1016/j.ijpharm.2019.03.051. Epub 2019 Mar 26.
5
Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.喷雾干燥用于囊性纤维化生物膜治疗的可吸入多功能制剂。
J Control Release. 2019 Nov 28;314:62-71. doi: 10.1016/j.jconrel.2019.10.038. Epub 2019 Oct 22.
6
Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery. Design and characterization.载左氧氟沙星和 DNA 酶的智能脂质纳米粒经肺部给药的设计与表征。
Colloids Surf B Biointerfaces. 2016 Jul 1;143:168-176. doi: 10.1016/j.colsurfb.2016.03.040. Epub 2016 Mar 15.
7
Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis.用于治疗与囊性纤维化相关的铜绿假单胞菌感染的多粘菌素甲磺酸钠负载脂质纳米载体
Int J Pharm. 2014 Dec 30;477(1-2):485-94. doi: 10.1016/j.ijpharm.2014.10.048. Epub 2014 Oct 24.
8
-Acetyl-l-cysteine-Loaded Nanosystems as a Promising Therapeutic Approach Toward the Eradication of Biofilms.乙酰半胱氨酸载纳米系统:一种有前途的治疗生物膜的方法。
ACS Appl Mater Interfaces. 2021 Sep 15;13(36):42329-42343. doi: 10.1021/acsami.1c05124. Epub 2021 Aug 31.
9
Evaluation of the Mucoadhesive Properties of Chitosan-Based Microstructured Lipid Carrier (CH-MLC).基于壳聚糖的微结构脂质载体(CH-MLC)的黏膜黏附特性评估
Pharmaceutics. 2022 Jan 12;14(1):170. doi: 10.3390/pharmaceutics14010170.
10
The Interaction of N-Acetylcysteine and Serum Transferrin Promotes Bacterial Biofilm Formation.N-乙酰半胱氨酸与血清转铁蛋白的相互作用促进细菌生物膜形成。
Cell Physiol Biochem. 2018;45(4):1399-1409. doi: 10.1159/000487566. Epub 2018 Feb 15.

引用本文的文献

1
Synergistic action of mucoactive drugs and phages against and .黏液活性药物与噬菌体对……的协同作用。 (原文中“against”后面内容缺失,翻译只能到此为止)
Microbiol Spectr. 2025 Mar 4;13(3):e0160124. doi: 10.1128/spectrum.01601-24. Epub 2025 Feb 6.
2
Advances in the Use of -Acetylcysteine in Chronic Respiratory Diseases.N-乙酰半胱氨酸在慢性呼吸道疾病中的应用进展
Antioxidants (Basel). 2023 Sep 2;12(9):1713. doi: 10.3390/antiox12091713.
3
N-acetylcysteine (NAC) and Its Role in Clinical Practice Management of Cystic Fibrosis (CF): A Review.

本文引用的文献

1
Association among serum and salivary A. actinomycetemcomitans specific immunoglobulin antibodies and periodontitis.血清和唾液中 A. actinomycetemcomitans 特异性免疫球蛋白抗体与牙周炎的关系。
BMC Oral Health. 2020 Oct 15;20(1):283. doi: 10.1186/s12903-020-01258-5.
2
Evaluation of salivary and serum asymmetric dimethylarginine (ADMA) levels in patients with periodontal and cardiovascular disease as subclinical marker of cardiovascular risk.评估牙周病和心血管疾病患者唾液及血清中不对称二甲基精氨酸(ADMA)水平,作为心血管风险的亚临床标志物。
J Periodontol. 2020 Aug;91(8):1076-1084. doi: 10.1002/JPER.19-0446. Epub 2020 Jan 27.
3
N-乙酰半胱氨酸(NAC)及其在囊性纤维化(CF)临床实践管理中的作用:综述
Pharmaceuticals (Basel). 2022 Feb 11;15(2):217. doi: 10.3390/ph15020217.
4
Evaluation of the Mucoadhesive Properties of Chitosan-Based Microstructured Lipid Carrier (CH-MLC).基于壳聚糖的微结构脂质载体(CH-MLC)的黏膜黏附特性评估
Pharmaceutics. 2022 Jan 12;14(1):170. doi: 10.3390/pharmaceutics14010170.
5
A Natural Alternative Treatment for Urinary Tract Infections: Itxasol©, the Importance of the Formulation.用于治疗尿路感染的天然替代疗法:Itxasol©,制剂的重要性。
Molecules. 2021 Jul 28;26(15):4564. doi: 10.3390/molecules26154564.
The Role of Drug Repurposing in the Development of Novel Antimicrobial Drugs: Non-Antibiotic Pharmacological Agents as Quorum Sensing-Inhibitors.
药物重新利用在新型抗菌药物研发中的作用:非抗生素类药理剂作为群体感应抑制剂
Antibiotics (Basel). 2019 Dec 17;8(4):270. doi: 10.3390/antibiotics8040270.
4
Vibrational Spectroscopy Fingerprinting in Medicine: from Molecular to Clinical Practice.医学中的振动光谱指纹识别:从分子到临床实践
Materials (Basel). 2019 Sep 6;12(18):2884. doi: 10.3390/ma12182884.
5
Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing.通过 AsCas12a 基因组编辑实现囊性纤维化剪接突变的等位基因特异性修复。
Nat Commun. 2019 Aug 7;10(1):3556. doi: 10.1038/s41467-019-11454-9.
6
Drug repurposing for antimicrobial discovery.药物重用以发现抗菌药物。
Nat Microbiol. 2019 Apr;4(4):565-577. doi: 10.1038/s41564-019-0357-1. Epub 2019 Mar 4.
7
Anti-biofilm effects of anthranilate on a broad range of bacteria.邻氨基苯甲酸对多种细菌的抗生物膜作用。
Sci Rep. 2017 Aug 17;7(1):8604. doi: 10.1038/s41598-017-06540-1.
8
Development and characterization of new and scalable topical formulations containing N-acetyl-d-glucosamine-loaded solid lipid nanoparticles.含载N-乙酰-d-葡萄糖胺固体脂质纳米粒的新型可扩展外用制剂的研发与特性研究
Drug Dev Ind Pharm. 2017 Nov;43(11):1792-1800. doi: 10.1080/03639045.2017.1339083. Epub 2017 Jun 21.
9
Background and Epidemiology.背景与流行病学。
Pediatr Clin North Am. 2016 Aug;63(4):567-84. doi: 10.1016/j.pcl.2016.04.001.
10
Effect of inhaled N-acetylcysteine monotherapy on lung function and redox balance in idiopathic pulmonary fibrosis.吸入性N-乙酰半胱氨酸单一疗法对特发性肺纤维化肺功能和氧化还原平衡的影响。
Respir Investig. 2016 May;54(3):170-8. doi: 10.1016/j.resinv.2015.11.004. Epub 2015 Dec 30.